Pooled Analysis of S-1 Trials in Non-Small Cell Lung Cancer According to Histological Type
7 O/ k5 [* T# V- sNOBUYUKI YAMAMOTO1, TAKEHARU YAMANAKA2, YUKITO ICHINOSE3, KAORU KUBOTA4, HIROSHI SAKAI5, AKIHIKO GEMMA6, NAGAHIRO SAIJO7, MASAHIRO FUKUOKA8 and HISANOBU NIITANI9 ( o5 u6 v& g6 |8 |/ m6 A
+ Author Affiliations9 R8 Q* n% o7 \6 T1 x9 o
' U, m2 r' c, ^: |. B- I
1Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan ; M5 D. D7 ^. M, U/ y2 P5 q4 D, I) N
2Cancer Biostatistics Laboratory, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
' U- e! m: F% K2 q3Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan 0 e% t, J' w. |
4Division of Thoracic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan
2 e& v4 u2 s+ a q5Division of Thoracic Oncology, Saitama Cancer Center, Saitama 362-0806, Japan
m- [5 o3 C8 W5 {$ S% [6Division of Pulmonary Medicine, Infectious Diseases, and Oncology Department of Internal Medicine, Nippon Medical School, Tokyo 113-8603, Japan . K% J% ^, o, o- [, {7 q5 `/ A( r- k
7Kinki University School of Medicine, Osaka 589-8511, Japan ! I z7 f- Z2 g# e3 O
8Izumi Municipal Hospital, Osaka 594-0071, Japan ! g4 H! T0 L+ C& n. t; B
9Tokyo Cooperative Oncology Group, Tokyo 105-0013, Japan
2 `6 t$ |. C4 d) [8 P# o+ |Correspondence to: Nobuyuki Yamamoto, Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. Tel: +81 559895222, Fax: +81 559895783, e-mail: n.yamamoto@scchr.jp * T6 _7 Y0 H; a9 `
AbstractBackground: The antimetabolic agent S-1 inhibits thymidylate synthase similar to pemetrexed, but through a different mechanism of action. Whether the antitumour activity of S-1 depends on histological type remains unclear. We analysed pooled data from 2 phase II clinical studies of cisplatin and S-1 in patients with previously untreated advanced non-small cell lung cancer. Patients and Methods: We comprised 110 patients with stage IIIB or IV non–small cell lung cancer. Univariate and multivariate analyses were performed to determine the effects of histological type on progression-free survival and response rates. Results: On pooled analysis of the data, according to histological type, median progression-free survival was 3.8 months in patients with squamous cell carcinoma and 4.4 months in those with non-squamous cell carcinoma. Both analyses showed that progression-free survival and response rate did not differ significantly. Conclusion: Unlike molecular targeted agents and pemetrexed, a combination of cisplatin and S-1 may be no difference in response according to histological type. 2 M) a2 ~7 _3 q' n) F7 @4 `
3 u9 b$ ?# p" w5 B& n; h0 { |